Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new eye injection protect vision in geographic atrophy?

NCT ID NCT07807969

Disease control Sponsor: Annexon, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study tests the long-term safety of vonaprument, an experimental drug given as an injection into the eye, for people with geographic atrophy, a severe form of dry age-related macular degeneration that causes blind spots. Researchers will monitor participants who completed an earlier phase 3 trial to see how their bodies handle repeated doses over a longer period. The main goal is to track any side effects, not to measure how well the drug preserves vision.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vonaprument (ANX007), given as an injection into the eye
What this could lead to
If successful, this study could support vonaprument as a long-term treatment option to slow the progression of geographic atrophy and help preserve vision.
What could go wrong
This is an extension study focused on safety, not on proving the drug works. Participants may still experience side effects from repeated eye injections, and the treatment may not halt vision loss for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 605 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with a diagnosis of dry AMD with GA who completed the Phase 3 ARCHER II study (NCT06510816) and who had not permanently ceased receiving the assigned masked treatment (IVT or Sham administration) at/before the ARCHER II Month 24 Visit. Exclusion Criteria: * Any event or condition arising during the ARCHER II study that would put the participant in danger or lead to undue harm by participating in this OLE study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Geographic atrophy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry age related macular degeneration Geographic Atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Geographic atrophy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    7 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Asheville Eye Associates - Retina Division

    Asheville, North Carolina, 28803, United States

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland, 21740, United States

  • Mid Atlantic Retina Specialists

    Hagerstown, Maryland, 21740, United States

  • Retina Group of Florida

    Sarasota, Florida, 34233, United States

  • Retina Research Institute at New England Retina Consultants

    Springfield, Massachusetts, 01107, United States

  • Retina Vitreous Associates of Florida

    St. Petersburg, Florida, 33711, United States

  • Verum Research, LLC

    Eugene, Oregon, 97401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.